Grant: CIHR Fellowship
University of Toronto
$110,000.00
Association Between Allopurinol and Cardiovascular Events, Mortality and End-Stage Renal Disease in Diabetes
FY 2017-18
Summary
Project Summary: Allopurinol is a medication that is traditionally used in patients with gout to lower uric acid levels. More recently it has been recognized that in addition to causing gout, elevated uric acid levels case systemic inflammation and high blood pressure, which increases the risk of heart disease, death, and kidney disease. High uric acid levels are common in people with diabetes. However, no large studies have evaluated whether people with diabetes and gout who are taking allopurinol have a lower risk of cardiovascular disease, death and kidney disease compared to those who are not taking allopurinol. The Institute for Clinical Evaluative Sciences (ICES) collects health care data on all Ontario individuals eligible for health insurance for administrative purposes. We will use this data to study the relationship between allopurinol and heart disease, death and kidney disease in people with diabetes.
Anticipated Outcomes: We believe there is a sufficient number of individuals with both diabetes and gout (high uric acid levels) in Ontario to answer the research question. We hypothesize that allopurinol is associated with a reduction in heart disease, death and kidney disease in patients with diabetes and high uric acid levels.
Importance: If the hypothesis is correct, these results could lead to further confirmatory studies and a wider role for the use of allopurinol in patients with diabetes to prevent heart disease, death and kidney disease. This would be important to those with diabetes and physicians who care for patients with diabetes. Allopurinol is inexpensive, safe and would be readily available for use if a benefit were found. If the hypothesis is correct, this could have a large impact since diabetes is very common, and heart disease and kidney disease are serious complications of diabetes.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
377029
Name
Weisman Alanna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Health Research Training B - HP
Projecttitle
Association Between Allopurinol and Cardiovascular Events, Mortality and End-Stage Renal Disease in Diabetes
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$110,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Administrative Data; Cardiovascular Outcomes; Diabetes; Epidemiology; Gout; Pharmacoepidemiology; Population Health; Renal Outcomes; Survival Analysis; Uric Acid
Abstract
Project Summary: Allopurinol is a medication that is traditionally used in patients with gout to lower uric acid levels. More recently it has been recognized that in addition to causing gout, elevated uric acid levels case systemic inflammation and high blood pressure, which increases the risk of heart disease, death, and kidney disease. High uric acid levels are common in people with diabetes. However, no large studies have evaluated whether people with diabetes and gout who are taking allopurinol have a lower risk of cardiovascular disease, death and kidney disease compared to those who are not taking allopurinol. The Institute for Clinical Evaluative Sciences (ICES) collects health care data on all Ontario individuals eligible for health insurance for administrative purposes. We will use this data to study the relationship between allopurinol and heart disease, death and kidney disease in people with diabetes.
Anticipated Outcomes: We believe there is a sufficient number of individuals with both diabetes and gout (high uric acid levels) in Ontario to answer the research question. We hypothesize that allopurinol is associated with a reduction in heart disease, death and kidney disease in patients with diabetes and high uric acid levels.
Importance: If the hypothesis is correct, these results could lead to further confirmatory studies and a wider role for the use of allopurinol in patients with diabetes to prevent heart disease, death and kidney disease. This would be important to those with diabetes and physicians who care for patients with diabetes. Allopurinol is inexpensive, safe and would be readily available for use if a benefit were found. If the hypothesis is correct, this could have a large impact since diabetes is very common, and heart disease and kidney disease are serious complications of diabetes.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Weisman, Alanna
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $110,000~ $0~